Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pediatric PK and HPA-axis safety study of Duobrii lotion in moderate to severe plaque psoriasis
2024-520057-20-00Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of halobetasol propionate + tazarotene in plaque psoriasis, sponsored by Valeant Pharmaceuticals. Primary endpoints: Safety of IDP-118 lotion administered topically once daily, Systemic exposure of halobetasol propionate, tazarotene, and tazarotenic acid and 1 more. Started Jan 2025; status: completed.
02
Drugs
halobetasol propionate + tazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2024-520057-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520057-20-00.